Christopher Sarchi has sold REPL and made no open-market buys since Nov 2023

Sarchi Christopher (often referred to as Chris Sarchi) is a biopharmaceutical commercial executive and corporate insider who serves as Chief Commercial Officer (CCO) of Replimune Group, Inc. (NASDAQ: REPL), a clinical‑stage oncology company focused on oncolytic immunotherapies.( In this role, he is responsible for building and leading Replimune’s commercial organization, including launch planning and market strategy for the company’s pipeline of cancer therapies, and he is a reporting insider in Replimune’s SEC filings and equity compensation programs.( Recent Form 4 disclosures show that he has been granted stock options and restricted stock units as part of his compensation, reinforcing his status as a key member of the company’s executive leadership team.(

Sarchi brings more than two decades of oncology commercial experience, including prior senior leadership roles in U.S. oncology at Sanofi, where he led commercial oncology efforts and oversaw multiple product launches and indications across tumor types.( Industry coverage notes that his career has centered on building and leading oncology commercial teams, driving new product launches, and shaping market access and physician engagement strategies in oncology.( Publicly available sources focus on his executive and commercial track record; detailed educational history is not disclosed in the referenced materials.(

Written by Perplexity from public sources.